优化策略树辅助结直肠癌肝转移切除术后辅助治疗决策
基于国际多机构数据库2000至2020年间1358例结直肠癌肝转移根治性切除患者,采用最优策略树分析确定辅助化疗对各亚组总生存和无复发生存的最佳分配。辅助化疗与更优无复发生存相关(3年无复发生存率:辅助化疗组54.4% vs 无辅助化疗组46.8%,P<.001),但总生存无显著改善(5年总生存率:辅助化疗组68.1% vs 无辅助化疗组65.7%,P=.15)。
要点
- 辅助化疗与更优无复发生存相关,但总生存无显著改善。
- 最优策略树依据患者人口学、继发肿瘤和原发肿瘤特征界定获益亚群。
- 随机森林模型在预测辅助化疗的反事实死亡和复发概率方面表现良好。
核心结论
- 基于患者、原发肿瘤和治疗特征的新型人工智能方法可能帮助临床医生在结直肠癌肝转移切除术后个体化制定辅助化疗建议。
研究设计与样本
- 研究为国际多机构数据库的回顾性分析,纳入2000至2020年间接受根治性意图切除的结直肠癌肝转移患者。
- 共纳入1358例患者,其中1032例(76.0%)接受辅助化疗。
- 采用最优策略树分析确定辅助化疗对患者亚组在总生存和无复发生存方面的最佳分配。
- 患者被随机分配为训练数据集(n=679)和测试数据集(n=679)。
主要发现
- 中位随访28.7个月(四分位距13.7-52.0),5年总生存率为67.5%,3年无复发生存率为52.6%。
- 辅助化疗与更优无复发生存相关(3年无复发生存率:辅助化疗组54.4% vs 无辅助化疗组46.8%,P<.001)。
- 辅助化疗与总生存无显著改善相关(5年总生存率:辅助化疗组68.1% vs 无辅助化疗组65.7%,P=.15)。
- 随机森林模型在预测辅助化疗的反事实死亡和复发概率方面表现良好。
- 根据最优策略树,患者人口学特征、继发肿瘤特征和原发肿瘤特征界定了可从辅助化疗中获益的亚群。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although systemic postoperative therapy after surgery for colorectal liver metastases is generally recommended, the benefit of adjuvant chemotherapy has been debated. We used machine learning to develop a decision tree and define which patients may benefit from adjuvant chemotherapy after hepatectomy for colorectal liver metastases. METHODS: Patients who underwent curative-intent resection for colorectal liver metastases between 2000 and 2020 were identified from an international multi-institutional database. An optimal policy tree analysis was used to determine the optimal assignment of the adjuvant chemotherapy to subgroups of patients for overall survival and recurrence-free survival. RESULTS: Among 1,358 patients who underwent curative-intent resection of colorectal liver metastases, 1,032 (76.0%) received adjuvant chemotherapy. After a median follow-up of 28.7 months (interquartile range 13.7-52.0), 5-year overall survival was 67.5%, and 3-year recurrence-free survival was 52.6%, respectively. Adjuvant chemotherapy was associated with better recurrence-free survival (3-year recurrence-free survival: adjuvant chemotherapy, 54.4% vs no adjuvant chemotherapy, 46.8%; P < .001) but no overall survival significant improvement (5-year overall survival: adjuvant chemotherapy, 68.1% vs no adjuvant chemotherapy, 65.7%; P = .15). Patients were randomly allocated into 2 cohorts (training data set, n = 679, testing data set, n = 679). The random forest model demonstrated good performance in predicting counterfactual probabilities of death and recurrence relative to receipt of adjuvant chemotherapy. According to the optimal policy tree, patient demographics, secondary tumor characteristics, and primary tumor characteristics defined the subpopulation that would benefit from adjuvant chemotherapy. CONCLUSION: A novel artificial intelligence methodology based on patient, primary tumor, and treatment characteristics may help clinicians tailor adjuvant chemotherapy recommendations after colorectal liver metastases resection.
引用
- Endo Y, Alaimo L, Moazzam Z, et al. Optimal policy tree to assist in adjuvant therapy decision-making after resection of colorectal liver metastases. Surgery. 2023. PMID: 37778970. doi:10.1016/j.surg.2023.06.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。